Category: Misc

• Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
• Ryan K, Bolaños B, Smith M, Palde P, Cuenca PD, VanArsdale TL, Niessen S, Zhang L, Behenna D, Ornelas MA, Tran KT, Kaiser S, Lum L, Stewart A, Gajiwala KS.
• J Biol Chem. 2020 Dec 24:jbc.RA120.016573. doi: 10.1074/jbc.RA120.016573. Epub ahead of print.

• PMID: 33361107
• PubMed abstract
• Source abstract

• Free Full Text (PDF)

• The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.
• Du ZH, Xia Y, Yang Q, Gao S.
• Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820983289. doi: 10.1177/1533033820983289. [First Published December 24, 2020.]

• PMID: 33357097
• PubMed abstract
• Source abstract

• Free Full Text

• MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/ß-catenin in serous ovarian cancers.
• Sun Y, Wu J, Dong X, Zhang J, Meng C, Liu G.
• Transl Oncol. 2020 Dec 21;14(2):100987. doi: 10.1016/j.tranon.2020.100987. Epub ahead of print.

• PMID: 33360300
• PubMed abstract

• Free Full Text

• Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
• Mehta AK, Cheney EM, Hartl CA, Pantelidou C, Oliwa M, Castrillon JA, Lin JR, Hurst KE, de Oliveira Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, Yélamos J, Thaxton JE, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL.
• Nat Cancer. 2020 Dec 14:1-2. doi: 10.1038/s43018-020-00148-7. Epub ahead of print.

• Source abstract

Related:

Research news: PARP Inhibitor Breast Cancer Treatments May Be Improved by Targeting Immunosuppressive Macrophages (Clinical OMICs)

• Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
• Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A, Kandalaft LE.
• Eur J Cancer. 2021 Jan;142:63-82. doi: 10.1016/j.ejca.2020.10.014. Epub 2020 Nov 19.

• PMID: 33221598
• PubMed abstract
• Source abstract

• Review

• PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
• Gralewska P, Gajek A, Marczak A, Mikula M, Ostrowski J, Sliwinska A, Rogalska A.
• Int J Mol Sci. 2020 Dec 19;21(24):E9715. doi: 10.3390/ijms21249715.

• PMID: 33352723
• PubMed abstract
• Source abstract

• Free Full Text

• PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
• Riad A, Gitto SB, Lee H, Winters HD, Martorano PM, Hsieh CJ, Xu K, Omran DK, Powell DJ Jr, Mach RH, Makvandi M.
• Molecules. 2020 Dec 19;25(24):E6029. doi: 10.3390/molecules25246029.

• PMID: 33352773
• PubMed abstract
• Source abstract

• Free Full Text

• Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profiling.
• Wei Y, Ou T, Lu Y, Wu G, Long Y, Pan X, Yao D.
• PeerJ. 2020 Nov 24;8:e10414. doi: 10.7717/peerj.10414.

• PMID: 33282564
• PubMed abstract

• Free PMC article
• Free Full Text

• Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer.
• Cheng HW, Chiang CS, Ho HY, Chou SH, Lai YH, Shyu WC, Chen SY.
• J Control Release. 2020 Dec 2:S0168-3659(20)30718-5. doi: 10.1016/j.jconrel.2020.11.061. Epub ahead of print.

• PMID: 33278482
• PubMed abstract
• Source abstract

• Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer.
• Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.
• Mol Cancer Ther. 2020 Dec 2:molcanther.0365.2020. doi: 10.1158/1535-7163.MCT-20-0365. Epub ahead of print.

• PMID: 33268569
• PubMed abstract
• Source abstract

• Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
• Wu X, Li Q, Zhang F, Wang L, Wang J, Fan J, Di G, Guo C.
• Food Chem Toxicol. 2020 Nov 30:111892. doi: 10.1016/j.fct.2020.111892. Epub ahead of print.

• PMID: 33271260
• PubMed abstract

• Free Full Text

• Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens.
• Clements KE, Schleicher EM, Thakar T, Hale A, Dhoonmoon A, Tolman NJ, Sharma A, Liang X, Imamura Kawasawa Y, Nicolae CM, Wang HG, De S, Moldovan GL.
• Nat Commun. 2020 Nov 30;11(1):6118. doi: 10.1038/s41467-020-19961-w.

• PMID: 33257658
• PubMed abstract

• Free Full Text

• Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
• Xiang HY, Chen JY, Huan XJ, Chen Y, Gao ZB, Ding J, Miao ZH, Yang CH.
• Bioorg Med Chem Lett. 2020 Nov 24:127710. doi: 10.1016/j.bmcl.2020.127710. Epub ahead of print.

• PMID: 33246105
• PubMed abstract

• Free Full Text

• Group Therapy for Patients With Medical Illness.
• Leszcz M.
• Am J Psychother. 2020 Oct 22:appipsychotherapy20200005. doi: 10.1176/appi.psychotherapy.20200005. Epub ahead of print.

• PMID: 33086863
• PubMed abstract
• Source abstract

• Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
• [No author given]
• GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.

• News
• Free Full Text

• Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
• Song L, Tang Z, Peng C, Yang Y, Guo C, Wang D, Guo L, Chen J, Liu C.
• BMC Cancer. 2020 Oct 21;20(1):1020. doi: 10.1186/s12885-020-07524-7.

• PMID: 33087072
• PubMed abstract

• Free Full Text

• Lessons learned from setting up a prospective, longitudinal, multicenter study with women at high risk for breast cancer.
• Patuleia SIS, Hagenaars SC, Moelans CB, Ausems MGEM, van Gils CH, Tollenaar RAEM, Van Diest PJ, Mesker WE, van der Wall E.
• Cancer Epidemiol Biomarkers Prev. 2020 Oct 20:cebp.0770.2020. doi: 10.1158/1055-9965.EPI-20-0770. Epub ahead of print.

• PMID: 33082203
• PubMed abstract

• Review

• Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
• Deligiorgi MV, Panayiotidis MI, Trafalis DT.
• Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.

• PMID: 33070648
• PubMed abstract
• Source abstract

• Review

• The abundance of the long intergenic non-coding RNA 01087 differentiates between luminal and triple-negative breast cancers and predicts patient outcome.
• De Palma FDE, Monaco VD, Pol JG, Kremer M, D'Argenio V, Stoll G, Montanaro D, Uszczynska-Ratajczak B, Klein CC, Vlasova A, Botti G, D'Aiuto M, Baldi A, Guigó R, Kroemer G, Maiuri MC, Salvatore F.
• Pharmacol Res. 2020 Oct 14:105249. doi: 10.1016/j.phrs.2020.105249. Epub ahead of print.

• PMID: 33068730
• PubMed abstract

• Free Full Text

• Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes.
• Singer CF.
• Horm Mol Biol Clin Investig. 2020 May 7;41(3):/j/hmbci.2020.41.issue-3/hmbci-2019-0057/hmbci-2019-0057.xml. doi: 10.1515/hmbci-2019-0057.

• PMID: 32989958
• PubMed abstract
• Source abstract

• Review

• Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.
• Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX.
• Am J Cancer Res. 2020 Sep 1;10(9):2813-2831.

• PMID: 33042619
• PubMed abstract
• ToC

• Free PMC article
• Free Full Text (PDF)